Activiomics has extended its Contract Research Agreement with Japanese pharmaceutical company Kyowa Hakko Kirin by entering into a new pharma alliances research programme.
Activiomics will apply its novel TIQUAS (Targeted In-depth QUAntification of cell Signalling) phosphoproteomics platform to elucidate signalling mechanisms generated by lead compounds supplied by KHK in relevant cell-based systems.
This pharma alliances falls within Activiomics’ strategic partnership with BioFocus.
Activiomics applies innovative mass spectrometry based methods to analyse and interpret cell signalling pathway activity resulting from drug administration and/or disease progression.
The company is utilising its technology for the discovery and clinical validation of novel prognostic and predictive biomarkers as well as to provide high-value drug mode of action information for the pharmaceutical and biotechnology industry.
For further deal information visit Current Agreements (subscription required)
Read: more on Kyowa Hakko Kirin company profile, recent partnering, M&A and financing news and articles
Report: Partnering Deals and Alliances with Kyowa Hakko Kirin
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity